ImaBiotech, along with pharmaceutical firm GlaxoSmithKline (GSK), will carry out a pilot study on mass spectrometric derived imaging technology in the ADME and toxicology fields.
ImaBiotec, a service provider for MALDI imaging, is said to focus on quantification challenges and volumetric imaging data interpretation through the development of specially adapted multimodal imaging methods and novel software called Multimaging.
Multimaging is a new advanced technology that will enhance the capacity of quantitative mass spectrometry imaging and classical histology techniques.
It holds the capability to quantitatively analyze the distribution of drug, metabolites and biomarkers at cellular level and offers the potential to accelerate drug pharmacokinetic, pharmacology and toxicity studies.
ImaBiotech CEO Dr Jonathan Stauber said: "We are very pleased with the initiation of a pilot study with a major pharmaceutical company.
"GSK’s interest in assessing ImaBiotech’s Multimaging technology further underscores the expertise of ImaBiotech in the imaging field and the potential benefits that Multimaging technology offers."
Image: Eye, brain, kidney and adrenal gland mass spectrometry images with Multimaging. Photo: courtesy of Business Wire.